Nishi Somarkutty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nishi Somarkutty has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Abi Manesh
Department of Infectious Diseases, Christian Medical College , Vellore, Tamil Nadu
1 shared publication- Appaswamy Thirumal Prabhakar
Department of Neurological Sciences, Christian Medical College Vellore, Tamil Nadu, India
1 shared publication - George M. Varghese
Department of Infectious Diseases, Christian Medical College, Vellore, India
1 shared publication - Harshad Arvind Vanjare
Department of Radiology, Christian Medical College Hospital, Vellore, Tamil Nadu, India
1 shared publication Jayavelu Hariram Prasad D
Department of Radiology, Christian Medical College , Vellore, Tamil Nadu
1 shared publicationJoy Sarojini Michael
Department of Clinical Microbiology, Christian Medical College , Vellore, Tamil Nadu
1 shared publication
Latest Publications
- 20 March 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (5) , 852-856
Role of Low-Dose Infliximab for Inflammatory Complications of Central Nervous System Tuberculosis: A Retrospective Cohort Study
We evaluated low-dose infliximab (5 mg/kg) as adjunctive therapy in 20 patients with severe central nervous system tuberculosis. At 3 months, 60% achieved disability-free survival (modified Rankin Scale ≤ 2), and 75% showed clinically meaningful improvement. Our outcomes matched reports of high-dose infliximab. Randomized trials to optimize dosing are needed.
- 20 March 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (5) , 852-856
Role of Low-Dose Infliximab for Inflammatory Complications of Central Nervous System Tuberculosis: A Retrospective Cohort Study
We evaluated low-dose infliximab (5 mg/kg) as adjunctive therapy in 20 patients with severe central nervous system tuberculosis. At 3 months, 60% achieved disability-free survival (modified Rankin Scale ≤ 2), and 75% showed clinically meaningful improvement. Our outcomes matched reports of high-dose infliximab. Randomized trials to optimize dosing are needed.